Medical Innovation Exchange

ESMO: Adding bempeg to Opdivo lowered response rate in Bristol Myers-Nektar failed cancer trial

https://www.fiercebiotech.com/biotech/esmo-adding-bempeg-opdivo-lowered-response-rate-bristol-myers-nektars-failed-cancer-trial

Leave a Comment

Your email address will not be published.

Leave the field below empty!